Ulimorelin

Summary

Ulimorelin (CHEMBL1963249) is a phase-3 clinical-stage small molecule; indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 4
• Chemistry: 538.7 Da · C30H39FN4O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1963249
Name	Ulimorelin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	11526696
Molecular formula	C30H39FN4O4
Molecular weight	538.7
InChIKey	WGYPAJVJMXQXTR-ABNZCKJZSA-N

SMILES: C[C@@H]1CN[C@H](C(=O)N([C@@H](C(=O)N[C@@H](C(=O)NCCCC2=CC=CC=C2O1)CC3=CC=C(C=C3)F)C)C)C4CC4

IUPAC name: (3R,6S,9R,12R)-6-cyclopropyl-12-[(4-fluorophenyl)methyl]-3,8,9-trimethyl-2-oxa-5,8,11,14-tetrazabicyclo[16.4.0]docosa-1(22),18,20-triene-7,10,13-trione

Also known as: TZP-101 FREE BASE, Ulimorelin, Ulimorelina, Ulimoreline, ULIMORELIN

Parent form; salt/anhydrous children: CHEMBL1923502, CHEMBL3926779

Patent coverage: 47 distinct patent families (103 SureChEMBL compound mentions), from 2 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Cytochrome P450 2D6, Cytochrome P450 2C9, Cytochrome P450 3A4, Growth hormone secretagogue receptor type 1.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
GHSR	9	EC50	1	nM	CHEMBL_ACT_16864411
GHSR	8.3	EC50	5	nM	CHEMBL_ACT_16864908
GHSR	7.57	EC50	27	nM	CHEMBL_ACT_12187758
CYP3A4	5.62	IC50	2400	nM	CHEMBL_ACT_29077865

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4).

The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE1	3
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02784392	PHASE2	COMPLETED	Efficacy, Safety, and Pharmacokinetics (PK) Study of Ulimorelin in Patients With Enteral Feeding Intolerance (EFI): The PROMOTE Trial
NCT01405599	PHASE1	COMPLETED	Evaluation of the Pharmacokinetics of Ulimorelin in Subjects With Hepatic Impairment and Healthy Subjects
NCT01405612	PHASE1	COMPLETED	Study to Examine the Effect of Ulimorelin on the Pharmacokinetics of Midazolam in Healthy Volunteers
NCT02993055	PHASE1	COMPLETED	A Study to Assess Ulimorelin in Healthy Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).